Pfizer expects to have safety and efficacy data for its COVID-19 vaccine in children in late September

Pfizer expects to have safety and efficacy data for its COVID-19 vaccine in children in late September
·1 min read

Pfizer Inc. expects to share data about the safety and efficacy of the COVID-19 vaccine it developed with BioNTech SE for children between the ages of 5 and 11 years old by the end of September, with plans to file for emergency authorization in the U.S. in early October, according to remarks made by company executives on Tuesday. Clinical data for children 6 months old to 5 years old is expected shortly after. "All of that depends on having a positive outcome on the data, right? I'm assuming tha

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting